Skip to main content
Premium Trial:

Request an Annual Quote

Lion’s Potenzone Signs on to Plan Strategy at Ingenuity


After nearly a year of trying to spin out a company based on an ADME/tox prediction technology from Lion Bioscience, Rudy Potenzone raised the white flag and looked for another opportunity. That came in the form of Ingenuity Systems, a pathway analysis company based in Mountain View, Calif., where Potenzone began in March as the new senior vice president of business development and strategic planning.

Potenzone’s last post was CEO of Lion’s US operations, and he was also in charge of planning strategy for the whole company. He left Lion at the end of March 2003 with the goal of forming a company from the ADME/tox technology, but “it’s such a miserable time for funding for a software business,” he says. “We had some success and we raised some interest, but not enough to start a company.”

So he called up Jake Leschly, president of Ingenuity, whom he had known for several years through a mutual friend, and found that his background in cheminformatics and his business experience were just what the company was looking for. “They needed someone who could come in at a pretty senior level and prioritize all the business and partnering opportunities,” he says of the five-year-old company that just launched a commercial product late last year.

Ingenuity started out with six founders who entered and won a Stanford entrepreneur business competition, which gave them the seed funding they needed to start the firm in 1998. Ingenuity’s premise was to create a database that would make sense of gene expression data by comparing it to genes, proteins, and marker information found in scientific literature using a proprietary ontology developed by the company’s employees, Potenzone says. “We’ve actually encoded a lot of known pathways into the database,” which can then be used to map new expression data back to the system, he adds.

Ingenuity’s staff spent four years building the tool, and now it’s Potenzone’s job to figure out how to get that technology out to the scientists. A first push using a free two-week Web trial is going well, he reports. In the short term, he’ll focus on pharma researchers in the early phase of discovery, but he says the tool’s genomics and proteomics data has strong potential for preclinical and even clinical users as well.

— Meredith Salisbury


The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.